Idera Pharma (IDRA) Reports In-Line Q3 Loss; Discontinues IMO-2125 Testing
Tweet
Share
E-mailGet Alerts IDRA Hot Sheet
Join SI Premium – FREE
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) reported Q3 loss of ($0.20), in-line with the analyst estimate of ($0.20). Revenue for the quarter came in at $4 million versus the consensus estimate of $2 million.
Based on its strategic assessment and prioritization, the Company has discontinued further development of IMO-2125 in hepatitis C virus infection and decided to advance its TLR-targeted programs in infectious diseases, respiratory diseases, hematologic oncology, and additional vaccine adjuvant applications only through licensing and partnering.
Based on its strategic assessment and prioritization, the Company has discontinued further development of IMO-2125 in hepatitis C virus infection and decided to advance its TLR-targeted programs in infectious diseases, respiratory diseases, hematologic oncology, and additional vaccine adjuvant applications only through licensing and partnering.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance
- Taylor Devices (TAYD) Misses Q4 EPS by 31c
- uCloudlink Group Inc. (UCL) Misses Q2 EPS by 1c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
